近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-09-11 | 30.91 | 1.48% | 473.19万 | 13.15% | -277.70万 | -7.72% | -195.49万 | -5.43% | | 2025-09-10 | 30.46 | 1.30% | e 75.77万 | 2.14% | -72.33万 | -2.04% | -3.45万 | -0.10% | | 2025-09-09 | 30.07 | -3.00% | 204.38万 | 4.12% | 428.72万 | 8.63% | -633.10万 | -12.75% | | 2025-09-08 | 31.00 | 4.20% | 127.31万 | 1.82% | 9.92万 | 0.14% | -137.24万 | -1.96% | | 2025-09-05 | 29.75 | 1.74% | ...

Core Viewpoint - Xiangsheng Medical (688358) experienced a decline in stock price and significant net outflow of funds on September 2, 2025, indicating potential investor concerns about the company's performance and market sentiment [1][2]. Financial Performance - As of September 2, 2025, Xiangsheng Medical's stock closed at 29.94 yuan, down 4.35% with a trading volume of 26,200 hands and a transaction amount of 79.1551 million yuan [1]. - The company reported a main revenue of 236 million yuan for the first half of 2025, a year-on-year decrease of 4.61%, and a net profit attributable to shareholders of 69.6963 million yuan, down 14.32% year-on-year [3]. - In Q2 2025, the company achieved a single-quarter main revenue of 108 million yuan, up 1.37% year-on-year, but the net profit attributable to shareholders decreased by 21.57% to 28.0818 million yuan [3]. Market Position and Ratios - Xiangsheng Medical's total market value is 3.357 billion yuan, with a net asset of 1.378 billion yuan and a net profit of 69.6963 million yuan, ranking 98th, 90th, and 45th respectively in the medical device industry [3]. - The company has a price-to-earnings ratio (P/E) of 24.08, significantly lower than the industry average of 65.2, indicating a potentially undervalued stock [3]. - The gross margin stands at 60.65%, higher than the industry average of 51.85%, while the net margin is 29.51%, compared to the industry average of 10.39% [3]. Fund Flow Analysis - On September 2, 2025, the main funds saw a net outflow of 12.2648 million yuan, accounting for 15.49% of the total transaction amount, while retail investors had a net inflow of 14.9967 million yuan, representing 18.95% of the total [1][2]. - Over the past five days, the stock has experienced fluctuating fund flows, with notable outflows from main funds on multiple days, indicating a trend of selling pressure [2]. Institutional Ratings - In the last 90 days, two institutions have given buy ratings for Xiangsheng Medical, suggesting some level of confidence in the company's future performance despite recent stock price declines [4].

Core Viewpoint - Xiangsheng Medical (688358) has experienced a decline in stock price and financial performance, indicating potential challenges in the medical device sector [1][4]. Stock Performance - As of August 29, 2025, Xiangsheng Medical's stock closed at 31.32 yuan, down 8.04% from the previous week [1]. - The stock reached a peak of 35.27 yuan on August 27, 2025, and a low of 30.96 yuan on August 29, 2025 [1]. - The company's current market capitalization is 3.512 billion yuan, ranking 102 out of 126 in the medical device sector and 4147 out of 5152 in the A-share market [1]. Shareholder Changes - As of June 30, 2025, the number of shareholders increased to 6,631, up by 122 from March 31, 2025, representing a growth of 1.87% [3][7]. - The average number of shares held per shareholder decreased from 17,200 shares to 16,900 shares, with an average holding value of 501,400 yuan [3]. Financial Performance - For the first half of 2025, Xiangsheng Medical reported a main revenue of 236 million yuan, a year-on-year decrease of 4.61% [4][7]. - The net profit attributable to shareholders was 69.696 million yuan, down 14.32% year-on-year [4][7]. - The second quarter of 2025 saw a main revenue of 108 million yuan, an increase of 1.37% year-on-year, but the net profit decreased by 21.57% to 28.0818 million yuan [4]. Company Announcements - The company plans to abolish the supervisory board, transferring its powers to the audit committee of the board of directors, pending approval at the 2025 first extraordinary general meeting [5][7]. - The company reported a net fundraising amount of 919 million yuan from its initial public offering, with 743 million yuan invested in projects by June 30, 2025 [5]. - Research and development expenses for the first half of 2025 amounted to 37.6131 million yuan, representing 15.93% of revenue, with R&D personnel accounting for 34.3% of the workforce [5]. - The company has signed an agreement with the Gates Foundation to jointly develop innovative obstetric and breast ultrasound equipment [5].

证券代码：688358 证券简称：祥生医疗 公告编号：2025-021 无锡祥生医疗科技股份有限公司 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 募集资金基本情况 (一) 实际募集资金金额、资金到账时间 经中国证券监督管理委员会《关于同意无锡祥生医疗科技股份有限公司首次 公开发行股票注册的批复》（证监许可[2019]2018 号）核准，无锡祥生医疗科技 股份有限公司（以下简称"公司"）于 2019 年 11 月向社会公开发行人民币普通股 （A 股）20,000,000 股，每股发行价格为人民币 50.53 元，募集资金总额为人民 币 1,010,600,000.00 元 ， 扣 除 发 行 费 用 后 实 际 募 集 资 金 净 额 为 人 民 币 业经容诚会计师事务所（特殊普通合伙）会验字[2019]8172 号《验资报告》验证。 公司对募集资金采取了专户存储管理。 (二) 本年度募集资金使用金额及年末余额 截至 2025 年 6 月 30 日，公司累计使用募集资金人民币 743,396,639.01 元投 入募 ...

Group 1 - The core viewpoint of the news is that Xiangsheng Medical's stock has experienced a decline of 5.03%, with a current price of 32.10 CNY per share and a total market capitalization of 3.599 billion CNY [1] - Xiangsheng Medical, established on January 30, 1996, specializes in the research, manufacturing, and sales of ultrasound medical imaging equipment, with 91.12% of its revenue coming from this segment [1] - The company is located in Wuxi, Jiangsu Province, and was listed on December 3, 2019 [1] Group 2 - According to fund holdings, Wan Jia Fund has a significant position in Xiangsheng Medical, with its Wan Jia Medical Quantitative Stock Mixed Fund A (020491) holding 9,400 shares, representing 1.95% of the fund's net value [2] - The fund has reported a year-to-date return of 29.76% and a one-year return of 56.72%, ranking 1937 out of 8190 and 1830 out of 7966 respectively [2] - The fund manager, Yin Hang, has been in position for 5 years and 40 days, with the fund's total asset size at 468 million CNY [3]

祥生医疗8月22日股价报收34.06元，较前一交易日上涨1.25%。盘中最高触及34.30元，最低33.74元，成 交金额达0.48亿元。 从资金流向来看，8月22日主力资金净流出442万元，近五个交易日累计净流出1100.5万元。当前公司总 市值38.19亿元，市净率为2.83。 来源：金融界 该公司属于医疗器械板块，主营业务为超声医学影像设备的研发、生产和销售。作为一家高新技术企 业，祥生医疗专注于超声医学影像领域的技术创新和产品开发。 风险提示：股市有风险，投资需谨慎。 ...

Core Viewpoint - Xiangsheng Medical (688358) has shown a slight increase in stock price, with a closing price of 33.92 yuan on August 19, 2025, reflecting a 0.95% rise, amidst mixed capital flows [1][2]. Financial Performance - The company reported a main revenue of 128 million yuan for Q1 2025, a year-on-year decrease of 9.16% [3]. - The net profit attributable to shareholders was 41.61 million yuan, down 8.62% year-on-year [3]. - The net profit after deducting non-recurring items was 38.87 million yuan, a decline of 13.38% year-on-year [3]. - The company's debt ratio stands at 9.84% [3]. Market Position - Xiangsheng Medical's total market capitalization is 3.803 billion yuan, significantly lower than the industry average of 12.117 billion yuan, ranking 95th out of 123 in the medical device industry [3]. - The company's net assets amount to 1.462 billion yuan, compared to the industry average of 3.898 billion yuan, ranking 86th [3]. - The price-to-earnings ratio (P/E) is 22.85, which is considerably lower than the industry average of 81.45, ranking 13th [3]. - The price-to-book ratio (P/B) is 2.82, compared to the industry average of 4.08, ranking 57th [3]. - The gross margin is 61.33%, higher than the industry average of 51.3%, ranking 48th [3]. - The net margin is 32.58%, significantly above the industry average of 10.7%, ranking 13th [3]. - Return on equity (ROE) is 2.89%, compared to the industry average of 1.28%, ranking 27th [3]. Capital Flow Analysis - On August 19, 2025, the net inflow of main funds was 2.2215 million yuan, accounting for 2.85% of the total transaction amount [1][2]. - Retail investors contributed a net inflow of 1.0292 million yuan, representing 1.32% of the total transaction amount [1][2]. - Over the past five days, the stock has experienced fluctuations in capital flow, with notable outflows from retail and speculative funds on certain days [2].

中国经济网北京8月15日讯祥生医疗(688358.SH)昨日晚间披露《股东减持股份计划公告》。 祥生医疗于2019年12月3日在上交所科创板上市，发行数量为2,000.00万股，发行价格为50.53元/股，保 荐机构(主承销商)为国金证券股份有限公司，保荐代表人俞乐、黎慧明。 公司上市发行募集资金总额101,060.00万元，扣除发行费用后，实际募集资金净额为91,949.44万元。 公司最终募集资金净额比原计划少3,394.33万元。公司上市前披露的招股说明书显示，公司拟募集资金 95,343.77万元，用于超声医学影像设备产业化项目，研发创新及营销运营基地建设项目，创新与发展储 备资金。 公司发行费用合计9,110.56万元(不含增值税金额)，其中承销及保荐费用7,374.20万元。 2022年6月30日，公司公告以每10股转增4股并税前派息5元，股权登记日2022年7月6日，除权除息日 2022年7月7日。 根据公告，股东莫若理拟自减持计划公告披露之日起15个交易日后的3个月内，通过集中竞价或大宗交 易的方式减持合计不超过所持公司股份3,363,735股，即不超过祥生医疗总股本的3.00%。其中以集中竞 ...

Company Overview - Xiangsheng Medical's closing price on August 14 was 33.85 yuan, down 2.17%, with a rolling PE ratio of 27.79 times and a total market capitalization of 3.795 billion yuan [1] - The company specializes in the research, manufacturing, and sales of ultrasound medical imaging equipment, and has been recognized as a "Little Giant" enterprise for 2024 by the national government [1] Financial Performance - For Q1 2025, Xiangsheng Medical reported revenue of 128 million yuan, a year-on-year decrease of 9.16%, and a net profit of 41.6145 million yuan, down 8.62% year-on-year, with a gross profit margin of 61.33% [1] Shareholder Information - As of March 31, 2025, the number of shareholders for Xiangsheng Medical was 6,509, an increase of 1,499 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Industry Comparison - The average PE ratio for the medical device industry is 55.76 times, with a median of 39.14 times, placing Xiangsheng Medical at the 55th position in the industry ranking [1][2] - The industry average market capitalization is 11.792 billion yuan, while the median is 5.679 billion yuan [2]

Core Viewpoint - Xiangsheng Medical (688358) has shown a recent stock price increase of 2.85% to 34.6 yuan, with a trading volume of 18,700 hands and a total transaction amount of 64.49 million yuan as of August 11, 2025 [1] Financial Performance - The company reported a main revenue of 128 million yuan in Q1 2025, a year-on-year decrease of 9.16% - The net profit attributable to shareholders was 41.61 million yuan, down 8.62% year-on-year - The net profit after deducting non-recurring gains and losses was 38.87 million yuan, a decline of 13.38% year-on-year - The debt ratio stands at 9.84%, with investment income of 910,800 yuan and financial expenses of -4.76 million yuan - The gross profit margin is 61.33% [2] Market Position - Xiangsheng Medical's total market value is 3.88 billion yuan, compared to the industry average of 11.897 billion yuan, ranking 94th out of 123 in the medical device industry - The company's net assets are 1.462 billion yuan, below the industry average of 3.899 billion yuan, ranking 86th - The net profit of 41.61 million yuan ranks 46th in the industry, with a price-to-earnings ratio of 23.31, significantly lower than the industry average of 68.73, ranking 16th - The price-to-book ratio is 2.87, compared to the industry average of 3.95, ranking 60th - The company's net profit margin is 32.58%, ranking 13th in the industry, while the return on equity (ROE) is 2.89%, ranking 24th [2] Investment Sentiment - In the last 90 days, one institution has given a buy rating for the stock [3]